Download PDF
Am J Perinatol 2023; 40(05): 467-474
DOI: 10.1055/a-1925-1532
SMFM Fellowship Series Article

Prospective Observational Study of N-terminal Pro–Brain Natriuretic Peptide Levels in Obese and Nonobese Women during Pregnancy

Anna E. Denoble    *
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Duke University Health System, Durham, North Carolina
,
Julia M. Moyett
2   Duke University School of Medicine, Duke University, Durham, North Carolina
,
Sarah A. Goldstein
3   Division of Cardiology, Department of Medicine, Duke University Health System, Durham, North Carolina
,
Cary C. Ward
3   Division of Cardiology, Department of Medicine, Duke University Health System, Durham, North Carolina
,
Tracy Truong
4   Department of Biostatistics and Bioinformatics, Duke University Health System, Durham, North Carolina
,
Alaattin Erkanli
4   Department of Biostatistics and Bioinformatics, Duke University Health System, Durham, North Carolina
,
Andra H. James
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Duke University Health System, Durham, North Carolina
,
Chad A. Grotegut
5   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Wake Forest Baptist Health System, Winston-Salem, North Carolina
› Author Affiliations Funding This study was generously supported by funding from the Duke Department of Obstetrics and Gynecology Hammond Research Fund. The Duke BERD Methods Core's support of this project was made possible in part by CTSA grant (UL1TR002553) from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NCATS or NIH.
› Further Information
    Permissions and Reprints

Abstract

Objective N-terminal pro–brain natriuretic peptide (NT-proBNP), a marker of ventricular dysfunction, varies by body mass index (BMI) outside of pregnancy. This study aimed to determine whether obesity affects NT-proBNP levels in pregnancy.

Study Design This was a prospective observational study of healthy pregnant people in the third trimester (3TM) and postpartum (PP). Patients were excluded if they had significant medical comorbidities or if their fetuses had anomalies, growth restriction or aneuploidy. NT-proBNP was measured at 28 weeks (3TM), predelivery (PD), 1 to 2 days PP (immediate postpartum [IPP]), and 4 to 6 weeks PP (delayed postpartum [DPP]). LogNT-proBNP levels were analyzed using linear mixed effects models, including BMI < or ≥30, time, and time-by-BMI interactions.

Results Fifty-five people (28 [51%] with BMI ≥ 30 and 27 [49%] with BMI < 30) were enrolled. A greater proportion of obese than nonobese subjects developed hypertensive disorders of pregnancy (50 vs. 15%, p = 0.010) and obese patients had higher systolic blood pressures at all time points (p < 0.05). NT-proBNP levels (median [interquartile range] in pg/mL) were 18 (6–28) versus 26 (17–48) at 3TM, 16 (3–38) versus 43 (21–60) at PD, 58 (20–102) versus 63 (38–155) at IPP, and 33 (27–56) versus 23 (8–42) at DPP for obese compared with nonobese patients. In linear mixed effects models, logNT-proBNP was lower in obese patients at 3TM (β = −0.89 [95% confidence interval, CI: −1.51, −0.26]) and PD (β = −1.05 [95% CI: −1.72, −0.38]). The logNT-proBNP trends over time differed by BMI category, with higher values in obese patients at both PP time points compared with the 3TM (IPP β = 1.24 [95% CI: 0.75, 1.73]; DPP β = 1.08 [95% CI: 0.52, 1.63]), but only IPP for nonobese patients (β = 0.87 [95% CI: 0.36, 1.38]).

Conclusion Obese patients had lower NT-proBNP levels than nonobese patients during pregnancy but not PP. The prolonged PP elevation in NT-proBNP in obese patients suggests that their PP cardiac recovery may be more prolonged.

Key Points

  • NT-proBNP levels are lower in obese than nonobese patients during pregnancy.

  • Levels remain elevated in obese, but not nonobese, patients up to 4 to 6 weeks' postpartum.

  • A lower threshold for concern regarding NT-proBNP levels may be needed in obese pregnant people.

Keywords

pregnancy - N-terminal pro–brain natriuretic peptide - brain natriuretic peptide - heart failure - obesity - peripartum cardiomyopathy

Conference Presentation

This manuscript was presented in poster format at the Society for Maternal-Fetal Medicine's 41st Annual Pregnancy Meeting (virtual), which was held on January 25–30, 2021.


Clinical Trial Registration

The study is registered with Clinical Trials.gov (https://clinicaltrials.gov/ct2/show/NCT04049136).


* Present address: Section of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT.




Publication History

Received: 12 January 2022

Accepted: 11 August 2022

Accepted Manuscript online:
16 August 2022

Article published online:
30 December 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Nakagawa O, Ogawa Y, Itoh H. et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload. J Clin Invest 1995; 96 (03) 1280-1287
    CrossrefPubMedGoogle Scholar
  • 2 Yancy CW, Jessup M, Bozkurt B. et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136 (06) e137-e161
    CrossrefPubMedGoogle Scholar
  • 3 Barasa A, Rosengren A, Sandström TZ, Ladfors L, Schaufelberger M. Heart failure in late pregnancy and postpartum: incidence and long-term mortality in Sweden from 1997 to 2010. J Card Fail 2017; 23 (05) 370-378
    CrossrefPubMedGoogle Scholar
  • 4 Tanous D, Siu SC, Mason J. et al. B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol 2010; 56 (15) 1247-1253
    CrossrefPubMedGoogle Scholar
  • 5 Burlingame JM, Yamasato K, Ahn HJ, Seto T, Tang WHW. B-type natriuretic peptide and echocardiography reflect volume changes during pregnancy. J Perinat Med 2017; 45 (05) 577-583
    CrossrefPubMedGoogle Scholar
  • 6 Mehra MR, Uber PA, Park MH. et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004; 43 (09) 1590-1595
    CrossrefPubMedGoogle Scholar
  • 7 Daniels LB, Clopton P, Bhalla V. et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. Am Heart J 2006; 151 (05) 999-1005
    CrossrefPubMedGoogle Scholar
  • 8 Wang TJ, Larson MG, Levy D. et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109 (05) 594-600
    CrossrefPubMedGoogle Scholar
  • 9 Yoshimura T, Yoshimura M, Yasue H. et al. Plasma concentration of atrial natriuretic peptide and brain natriuretic peptide during normal human pregnancy and the postpartum period. J Endocrinol 1994; 140 (03) 393-397
    CrossrefPubMedGoogle Scholar
  • 10 Madamanchi C, Alhosaini H, Sumida A, Runge MS. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol 2014; 176 (03) 611-617
    CrossrefPubMedGoogle Scholar
  • 11 McDonagh TA, Metra M, Adamo M. et al; ESC Scientific Document Group. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42 (36) 3599-3726
    CrossrefPubMedGoogle Scholar
  • 12 Heidenreich PA, Bozkurt B, Aguilar D. et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145 (18) e876-e894
    PubMedGoogle Scholar
  • 13 Zaphiriou A, Robb S, Murray-Thomas T. et al. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 2005; 7 (04) 537-541
    CrossrefPubMedGoogle Scholar
  • 14 Batal O, Faulx M, Krasuski RA. et al. Effect of obesity on B-type natriuretic peptide levels in patients with pulmonary arterial hypertension. Am J Cardiol 2012; 110 (06) 909-914
    CrossrefPubMedGoogle Scholar
  • 15 Bayes-Genis A, Lloyd-Jones DM, van Kimmenade RR. et al. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med 2007; 167 (04) 400-407
    CrossrefPubMedGoogle Scholar
  • 16 Khalid U, Wruck LM, Quibrera PM. et al. BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: the Atherosclerosis Risk in Communities Surveillance Study. Int J Cardiol 2017; 233: 61-66
    CrossrefPubMedGoogle Scholar
  • 17 Krauser DG, Lloyd-Jones DM, Chae CU. et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J 2005; 149 (04) 744-750
    CrossrefPubMedGoogle Scholar
  • 18 Giorgione V, O'Driscoll J, Coutinho CM. et al. Peripartum echocardiographic changes in women with hypertensive disorders of pregnancy. Ultrasound Obstet Gynecol 2022; 59 (03) 365-370
    CrossrefPubMedGoogle Scholar
  • 19 Davis EM, Ewald G, Givertz MM. et al; IPAC Investigators. Maternal obesity affects cardiac remodeling and recovery in women with peripartum cardiomyopathy. Am J Perinatol 2019; 36 (05) 476-483
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Fox ER, Musani SK, Bidulescu A. et al. Relation of obesity to circulating B-type natriuretic peptide concentrations in blacks: the Jackson Heart Study. Circulation 2011; 124 (09) 1021-1027
    CrossrefPubMedGoogle Scholar
  • 21 Das SR, Drazner MH, Dries DL. et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005; 112 (14) 2163-2168
    CrossrefPubMedGoogle Scholar
  • 22 Centers for Disease Control and Prevention. Adult Obesity Prevalence Maps. Published 2020. Updated September 21, 2020. Accessed January 26, 2021 at: https://www.cdc.gov/obesity/data/prevalence-maps.html
    PubMedGoogle Scholar